: Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction.
Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology / Raggi, Paolo; Milic, Jovana; Manicardi, Marcella; Cinque, Felice; Swain, Mark G.; Sebastiani, Giada; Guaraldi, Giovanni. - In: ATHEROSCLEROSIS. - ISSN 0021-9150. - 392:(2024), pp. 1-10. [10.1016/j.atherosclerosis.2024.117523]
Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
Manicardi, Marcella;Guaraldi, Giovanni
2024
Abstract
: Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction.File | Dimensione | Formato | |
---|---|---|---|
PIIS0021915024000832.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
3.28 MB
Formato
Adobe PDF
|
3.28 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris